In platinum-resistant ovarian cancer,

Glucocorticoid receptor activation opens a new perspective on chemoresistance

Stay informed with The Signal

Science that aims to
reach more women

Science that aims to reach more women

Emerging research elucidates a unique resistance mechanism in ovarian cancer¹

Platinum-resistant ovarian cancer (PROC) is an aggressive disease with poor prognosis and limited treatment options.² Biomarker-targeted treatments are available, but not all women are eligible.^3,4

PROC by the numbers

~85%

of patients will experience recurrence and become resistant to chemotherapy⁵

3-7 months

median progression-free survival with current treatment options⁶

~64%

are not eligible for FDA-approved biomarker therapy³

The Unmet
Need in PROC

Where is the unmet need in ovarian cancer? This is what leading oncologists are looking for in management.

An evolving scientific paradigm

Emerging research brings hope for clearer understanding

New science is shedding light on mechanisms of resistance. Studies have shown that chemotherapy
activity can be limited by cortisol-driven activation of the glucocorticoid receptor (GR), even at
physiological levels of cortisol.⁷

References:

1. Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al. Gynecol Oncol. 2017;146(1):153-160. 2. Greer A, Gockley A, Manning-Geist B, et al. Int J Gynecol Cancer. 2021;31(10):1341-1347. 3. Matulonis UA, Lorusso D, Oaknin A, et al. J Clin Oncol. 2023;41:2436-2445. 4. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA. March 22, 2024. Accessed December 11, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian 5. St Laurent J, Liu JF. J Clin Oncol. 2024;42(2):127-133. 6. Richardson DL, Eskander RN, O’Malley DM. JAMA Oncol. 2023;9(6):851-859. 7. Colombo N, Van Gorp T, Matulonis UA, et al. J Clin Oncol. 2023;41(30):4779-4789.